BIOMAT Database Logo BIOMAT Database Logo

Pentaerythritol tetranicotinate (niceritrol) decreases plasma lipoprotein(a) levels. 1997

K Tanaka, and K Hayashi, and T Shingu, and Y Kuga, and Y Okura, and Y Yasunobu, and H Ohtani, and S Nomura, and H Kurushima, and M Saeki, and M Kambe, and G Kajiyama
First Department of Internal Medicine, Hiroshima University School of Medicine, Japan.

We determined the most effective dosage of pentaerythritol tetranicotinate (niceritrol) to reduce plasma lipoprotein(a) [Lp(a)] levels in 44 Japanese patients (16 men and 28 women; mean age, 59.2 +/- 10.8 years) with hyperlipidemia types IIa, IIb, and IV. Patients received oral niceritrol at a dosage of 750 mg (3 tablets)/d for 8 weeks, followed by 1,500 mg (6 tablets)/d for 8 weeks. Administration of niceritrol 750 mg/d for 8 weeks decreased total and low-density lipoprotein (LDL) cholesterol in patients with type IIa hyperlipidemia and decreased triglycerides in patients with type IV hyperlipidemia, but did not affect Lp(a). However, niceritrol 1,500 mg/d for 8 weeks decreased Lp(a) in patients with initial Lp(a) levels greater than 30 mg/dL in addition to decreasing total and LDL cholesterol and triglycerides. These results suggest that the effective dosage of niceritrol to reduce the serum Lp(a) concentration in Japanese hyperlipidemic patients with a high Lp(a) level (> or = 30 mg/dL) is greater than 1,500 mg/d.

UI MeSH Term Description Entries
D008076 Cholesterol, HDL Cholesterol which is contained in or bound to high-density lipoproteins (HDL), including CHOLESTEROL ESTERS and free cholesterol. High Density Lipoprotein Cholesterol,Cholesterol, HDL2,Cholesterol, HDL3,HDL Cholesterol,HDL(2) Cholesterol,HDL(3) Cholesterol,HDL2 Cholesterol,HDL3 Cholesterol,alpha-Lipoprotein Cholesterol,Cholesterol, alpha-Lipoprotein,alpha Lipoprotein Cholesterol
D008078 Cholesterol, LDL Cholesterol which is contained in or bound to low density lipoproteins (LDL), including CHOLESTEROL ESTERS and free cholesterol. LDL Cholesterol,Cholesteryl Linoleate, LDL,LDL Cholesteryl Linoleate,Low Density Lipoprotein Cholesterol,beta-Lipoprotein Cholesterol,Cholesterol, beta-Lipoprotein,beta Lipoprotein Cholesterol
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009531 Niceritrol An ester of nicotinic acid that lowers cholesterol and triglycerides in total plasma and in the VLD- and LD-lipoprotein fractions. Pentaerythritol Tetranicotinate,Niceritrol Tetrahydrochloride,Pentaerythritoltetranicotinate,Perycit,Tetrahydrochloride, Niceritrol,Tetranicotinate, Pentaerythritol
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D000960 Hypolipidemic Agents Substances that lower the levels of certain LIPIDS in the BLOOD. They are used to treat HYPERLIPIDEMIAS. Antihyperlipidemic,Antilipemic,Antilipemic Agents,Antilipemic Drug,Hypolipidemic Agent,Hypolipidemic Drug,Antihyperlipemics,Antihyperlipidemics,Antilipemic Drugs,Antilipemics,Hypolipidemic Drugs,Agent, Hypolipidemic,Agents, Antilipemic,Agents, Hypolipidemic,Drug, Antilipemic,Drug, Hypolipidemic,Drugs, Antilipemic,Drugs, Hypolipidemic
D014280 Triglycerides An ester formed from GLYCEROL and three fatty acid groups. Triacylglycerol,Triacylglycerols,Triglyceride

Related Publications

K Tanaka, and K Hayashi, and T Shingu, and Y Kuga, and Y Okura, and Y Yasunobu, and H Ohtani, and S Nomura, and H Kurushima, and M Saeki, and M Kambe, and G Kajiyama
Effects of niceritrol (pentaerythritol tetranicotinate) on plasma lipoprotein concentration: increment of high density lipoprotein(HDL) cholesterol and HDL-cholesterol/low density lipoprotein cholesterol ratio in hypo-high density lipoproteinemia.
January 1982, Artery,
K Tanaka, and K Hayashi, and T Shingu, and Y Kuga, and Y Okura, and Y Yasunobu, and H Ohtani, and S Nomura, and H Kurushima, and M Saeki, and M Kambe, and G Kajiyama
Niceritrol reduces plasma lipoprotein(a) levels in patients undergoing maintenance hemodialysis.
January 1993, Renal failure,
K Tanaka, and K Hayashi, and T Shingu, and Y Kuga, and Y Okura, and Y Yasunobu, and H Ohtani, and S Nomura, and H Kurushima, and M Saeki, and M Kambe, and G Kajiyama
Dose-dependent effect of niceritrol on plasma lipoprotein-a.
July 1996, Scandinavian journal of clinical and laboratory investigation,
K Tanaka, and K Hayashi, and T Shingu, and Y Kuga, and Y Okura, and Y Yasunobu, and H Ohtani, and S Nomura, and H Kurushima, and M Saeki, and M Kambe, and G Kajiyama
[Niceritrol decreases serum phosphate levels in chronic hemodialysis patients].
January 1998, Nihon Jinzo Gakkai shi,
K Tanaka, and K Hayashi, and T Shingu, and Y Kuga, and Y Okura, and Y Yasunobu, and H Ohtani, and S Nomura, and H Kurushima, and M Saeki, and M Kambe, and G Kajiyama
The behavior of pentaerythritol tetranicotinate in rat gastrointestinal tract as a prodrug.
February 1981, Journal of pharmacobio-dynamics,
K Tanaka, and K Hayashi, and T Shingu, and Y Kuga, and Y Okura, and Y Yasunobu, and H Ohtani, and S Nomura, and H Kurushima, and M Saeki, and M Kambe, and G Kajiyama
Comparison of plasma levels of free nicotinic acid in rats and rabbits treated with nicotinic acid, pentaerythritol tetranicotinate (Perycit) and 2,6-pyridine dimethanol dinicotinoate.
November 1978, Il Farmaco; edizione pratica,
K Tanaka, and K Hayashi, and T Shingu, and Y Kuga, and Y Okura, and Y Yasunobu, and H Ohtani, and S Nomura, and H Kurushima, and M Saeki, and M Kambe, and G Kajiyama
Clinical and metabolic effects of pentaerythritol tetranicotinate in combination with cholesolvin or clofibrate.
January 1974, Atherosclerosis,
K Tanaka, and K Hayashi, and T Shingu, and Y Kuga, and Y Okura, and Y Yasunobu, and H Ohtani, and S Nomura, and H Kurushima, and M Saeki, and M Kambe, and G Kajiyama
Clinical and metabolic effects of pentaerythritol tetranicotinate(Perycit)and a comparison with plain nicotinic acid.
January 1974, Atherosclerosis,
K Tanaka, and K Hayashi, and T Shingu, and Y Kuga, and Y Okura, and Y Yasunobu, and H Ohtani, and S Nomura, and H Kurushima, and M Saeki, and M Kambe, and G Kajiyama
Plasma levels of nicotinic acid compounds in niceritrol-treated rabbits.
March 1975, Acta pharmacologica et toxicologica,
K Tanaka, and K Hayashi, and T Shingu, and Y Kuga, and Y Okura, and Y Yasunobu, and H Ohtani, and S Nomura, and H Kurushima, and M Saeki, and M Kambe, and G Kajiyama
Long-term effects of niceritrol on serum lipoprotein(a) and lipids in patients with high levels of lipoprotein(a).
January 1995, Clinical therapeutics,
Copied contents to your clipboard!